Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

SRXH vs ALHC vs HIMS vs CVS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SRXH
SRx Health Solutions Inc.

Drug Manufacturers - General

HealthcareNYSE • US
Market Cap$1M
5Y Perf.-94.2%
ALHC
Alignment Healthcare, Inc.

Medical - Healthcare Plans

HealthcareNASDAQ • US
Market Cap$3.73B
5Y Perf.+3.0%
HIMS
Hims & Hers Health, Inc.

Medical - Equipment & Services

HealthcareNYSE • US
Market Cap$6.63B
5Y Perf.-22.5%
CVS
CVS Health Corporation

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$111.40B
5Y Perf.+30.9%

SRXH vs ALHC vs HIMS vs CVS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SRXH logoSRXH
ALHC logoALHC
HIMS logoHIMS
CVS logoCVS
IndustryDrug Manufacturers - GeneralMedical - Healthcare PlansMedical - Equipment & ServicesMedical - Healthcare Plans
Market Cap$1M$3.73B$6.63B$111.40B
Revenue (TTM)$119M$4.26B$2.35B$407.90B
Net Income (TTM)$-11M$20M$128M$2.93B
Gross Margin19.9%9.0%69.7%13.9%
Operating Margin-4.9%0.8%4.6%1.5%
Forward P/E140.9x51.5x12.2x
Total Debt$39M$338M$1.12B$93.59B
Cash & Equiv.$2M$578M$229M$8.51B

SRXH vs ALHC vs HIMS vs CVSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SRXH
ALHC
HIMS
CVS
StockApr 25May 26Return
SRx Health Solution… (SRXH)1005.8-94.2%
Alignment Healthcar… (ALHC)100103.0+3.0%
Hims & Hers Health,… (HIMS)10077.5-22.5%
CVS Health Corporat… (CVS)100130.9+30.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: SRXH vs ALHC vs HIMS vs CVS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CVS leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Hims & Hers Health, Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
SRXH
SRx Health Solutions Inc.
The Lower-Volatility Pick

SRXH plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
ALHC
Alignment Healthcare, Inc.
The Insurance Play

ALHC lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
HIMS
Hims & Hers Health, Inc.
The Growth Play

HIMS is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.

  • Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
  • 161.9% 10Y total return vs ALHC's 5.4%
  • 59.0% revenue growth vs CVS's 7.8%
  • 5.5% margin vs SRXH's -9.4%
Best for: growth exposure and long-term compounding
CVS
CVS Health Corporation
The Insurance Pick

CVS carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • Dividend streak 0 yrs, beta 0.05, yield 3.1%
  • Lower volatility, beta 0.05, current ratio 0.84x
  • Beta 0.05, yield 3.1%, current ratio 0.84x
  • Lower P/E (12.2x vs 51.5x)
Best for: income & stability and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthHIMS logoHIMS59.0% revenue growth vs CVS's 7.8%
ValueCVS logoCVSLower P/E (12.2x vs 51.5x)
Quality / MarginsHIMS logoHIMS5.5% margin vs SRXH's -9.4%
Stability / SafetyCVS logoCVSBeta 0.05 vs HIMS's 2.40, lower leverage
DividendsCVS logoCVS3.1% yield; the other 3 pay no meaningful dividend
Momentum (1Y)CVS logoCVS+34.7% vs SRXH's -84.6%
Efficiency (ROA)HIMS logoHIMS6.0% ROA vs SRXH's -22.4%, ROIC 10.7% vs -18.1%

SRXH vs ALHC vs HIMS vs CVS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SRXHSRx Health Solutions Inc.

Segment breakdown not available.

ALHCAlignment Healthcare, Inc.
FY 2023
Health Care, Premium
92.6%$1.7B
Health Care Capitation
7.4%$133M
HIMSHims & Hers Health, Inc.

Segment breakdown not available.

CVSCVS Health Corporation
FY 2025
Pharmacy Revenue
58.9%$229.0B
Premiums
34.6%$134.8B
Front Store Revenue
5.5%$21.5B
Product and Service, Other
1.0%$3.9B

SRXH vs ALHC vs HIMS vs CVS — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLHIMSLAGGINGALHC

Income & Cash Flow (Last 12 Months)

Evenly matched — ALHC and HIMS each lead in 3 of 6 comparable metrics.

CVS is the larger business by revenue, generating $407.9B annually — 3429.5x SRXH's $119M. HIMS is the more profitable business, keeping 5.5% of every revenue dollar as net income compared to SRXH's -9.4%. On growth, ALHC holds the edge at +33.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSRXH logoSRXHSRx Health Soluti…ALHC logoALHCAlignment Healthc…HIMS logoHIMSHims & Hers Healt…CVS logoCVSCVS Health Corpor…
RevenueTrailing 12 months$119M$4.3B$2.3B$407.9B
EBITDAEarnings before interest/tax$66M$164M$10.5B
Net IncomeAfter-tax profit$20M$128M$2.9B
Free Cash FlowCash after capex$237M$73M$7.4B
Gross MarginGross profit ÷ Revenue+19.9%+9.0%+69.7%+13.9%
Operating MarginEBIT ÷ Revenue-4.9%+0.8%+4.6%+1.5%
Net MarginNet income ÷ Revenue-9.4%+0.5%+5.5%+0.7%
FCF MarginFCF ÷ Revenue+1.3%+5.6%+3.1%+1.8%
Rev. Growth (YoY)Latest quarter vs prior year+33.3%+28.4%+6.2%
EPS Growth (YoY)Latest quarter vs prior year+2.1%-27.3%+63.1%
Evenly matched — ALHC and HIMS each lead in 3 of 6 comparable metrics.

Valuation Metrics

CVS leads this category, winning 3 of 6 comparable metrics.

At 50.3x trailing earnings, HIMS trades at a 20% valuation discount to CVS's 62.8x P/E. On an enterprise value basis, CVS's 13.1x EV/EBITDA is more attractive than ALHC's 77.1x.

MetricSRXH logoSRXHSRx Health Soluti…ALHC logoALHCAlignment Healthc…HIMS logoHIMSHims & Hers Healt…CVS logoCVSCVS Health Corpor…
Market CapShares × price$1M$3.7B$6.6B$111.4B
Enterprise ValueMkt cap + debt − cash$29M$3.5B$7.5B$196.5B
Trailing P/EPrice ÷ TTM EPS-0.17x-4932.43x50.32x62.81x
Forward P/EPrice ÷ next-FY EPS est.140.93x51.51x12.19x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple77.12x42.68x13.11x
Price / SalesMarket cap ÷ Revenue0.02x0.94x2.82x0.28x
Price / BookPrice ÷ Book value/share20.16x12.25x1.47x
Price / FCFMarket cap ÷ FCF1.20x32.95x89.61x14.27x
CVS leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

HIMS leads this category, winning 4 of 9 comparable metrics.

HIMS delivers a 23.7% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $4 for CVS. CVS carries lower financial leverage with a 1.24x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), ALHC scores 6/9 vs SRXH's 3/9, reflecting solid financial health.

MetricSRXH logoSRXHSRx Health Soluti…ALHC logoALHCAlignment Healthc…HIMS logoHIMSHims & Hers Healt…CVS logoCVSCVS Health Corpor…
ROE (TTM)Return on equity+11.5%+23.7%+3.9%
ROA (TTM)Return on assets-22.4%+1.8%+6.0%+1.1%
ROICReturn on invested capital-18.1%+10.7%+5.0%
ROCEReturn on capital employed-98.8%+2.9%+10.9%+6.1%
Piotroski ScoreFundamental quality 0–93645
Debt / EquityFinancial leverage1.89x2.07x1.24x
Net DebtTotal debt minus cash$37M-$240M$892M$85.1B
Cash & Equiv.Liquid assets$2M$578M$229M$8.5B
Total DebtShort + long-term debt$39M$338M$1.1B$93.6B
Interest CoverageEBIT ÷ Interest expense-2.83x1.27x2.11x
HIMS leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — ALHC and HIMS and CVS each lead in 2 of 6 comparable metrics.

A $10,000 investment in HIMS five years ago would be worth $23,764 today (with dividends reinvested), compared to $536 for SRXH. Over the past 12 months, CVS leads with a +34.7% total return vs SRXH's -84.6%. The 3-year compound annual growth rate (CAGR) favors ALHC at 36.2% vs SRXH's -62.3% — a key indicator of consistent wealth creation.

MetricSRXH logoSRXHSRx Health Soluti…ALHC logoALHCAlignment Healthc…HIMS logoHIMSHims & Hers Healt…CVS logoCVSCVS Health Corpor…
YTD ReturnYear-to-date-52.9%-9.7%-23.2%+10.6%
1-Year ReturnPast 12 months-84.6%+17.6%-51.0%+34.7%
3-Year ReturnCumulative with dividends-94.6%+152.4%+116.6%+36.6%
5-Year ReturnCumulative with dividends-94.6%-22.7%+137.6%+17.0%
10-Year ReturnCumulative with dividends-94.6%+5.4%+161.9%+3.5%
CAGR (3Y)Annualised 3-year return-62.3%+36.2%+29.4%+11.0%
Evenly matched — ALHC and HIMS and CVS each lead in 2 of 6 comparable metrics.

Risk & Volatility

Evenly matched — SRXH and CVS each lead in 1 of 2 comparable metrics.

SRXH is the less volatile stock with a -0.32 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs SRXH's 9.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSRXH logoSRXHSRx Health Soluti…ALHC logoALHCAlignment Healthc…HIMS logoHIMSHims & Hers Healt…CVS logoCVSCVS Health Corpor…
Beta (5Y)Sensitivity to S&P 500-0.32x0.75x2.40x0.05x
52-Week HighHighest price in past year$1.25$23.87$70.43$88.63
52-Week LowLowest price in past year$0.08$11.63$13.74$58.35
% of 52W HighCurrent price vs 52-week peak+9.0%+76.5%+36.4%+98.5%
RSI (14)Momentum oscillator 0–10041.437.354.569.3
Avg Volume (50D)Average daily shares traded22.0M3.6M34.9M7.4M
Evenly matched — SRXH and CVS each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: ALHC as "Buy", HIMS as "Hold", CVS as "Buy". Consensus price targets imply 36.1% upside for ALHC (target: $25) vs 9.0% for CVS (target: $95). CVS is the only dividend payer here at 3.06% yield — a key consideration for income-focused portfolios.

MetricSRXH logoSRXHSRx Health Soluti…ALHC logoALHCAlignment Healthc…HIMS logoHIMSHims & Hers Healt…CVS logoCVSCVS Health Corpor…
Analyst RatingConsensus buy/hold/sellBuyHoldBuy
Price TargetConsensus 12-month target$24.83$29.67$95.20
# AnalystsCovering analysts161941
Dividend YieldAnnual dividend ÷ price+3.1%
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS$2.67
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+1.4%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

CVS leads in 1 of 6 categories (Valuation Metrics). HIMS leads in 1 (Profitability & Efficiency). 3 tied.

Best OverallHims & Hers Health, Inc. (HIMS)Leads 1 of 6 categories
Loading custom metrics...

SRXH vs ALHC vs HIMS vs CVS: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is SRXH or ALHC or HIMS or CVS a better buy right now?

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus 7. 8% for CVS Health Corporation (CVS). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 50. 3x trailing P/E (51. 5x forward), making it the more compelling value choice. Analysts rate Alignment Healthcare, Inc. (ALHC) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — SRXH or ALHC or HIMS or CVS?

On trailing P/E, Hims & Hers Health, Inc.

(HIMS) is the cheapest at 50. 3x versus CVS Health Corporation at 62. 8x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 2x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — SRXH or ALHC or HIMS or CVS?

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -94. 6% for SRx Health Solutions Inc. (SRXH). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus SRXH's -94. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — SRXH or ALHC or HIMS or CVS?

By beta (market sensitivity over 5 years), SRx Health Solutions Inc.

(SRXH) is the lower-risk stock at -0. 32β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately -844% more volatile than SRXH relative to the S&P 500. On balance sheet safety, CVS Health Corporation (CVS) carries a lower debt/equity ratio of 124% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — SRXH or ALHC or HIMS or CVS?

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus 7. 8% for CVS Health Corporation (CVS). On earnings-per-share growth, the picture is similar: Alignment Healthcare, Inc. grew EPS 99. 4% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — SRXH or ALHC or HIMS or CVS?

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -9. 4% for SRx Health Solutions Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 5. 2% versus -4. 9% for SRXH. At the gross margin level — before operating expenses — HIMS leads at 59. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is SRXH or ALHC or HIMS or CVS more undervalued right now?

On forward earnings alone, CVS Health Corporation (CVS) trades at 12.

2x forward P/E versus 140. 9x for Alignment Healthcare, Inc. — 128. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALHC: 36. 1% to $24. 83.

08

Which pays a better dividend — SRXH or ALHC or HIMS or CVS?

In this comparison, CVS (3.

1% yield) pays a dividend. SRXH, ALHC, HIMS do not pay a meaningful dividend and should not be held primarily for income.

09

Is SRXH or ALHC or HIMS or CVS better for a retirement portfolio?

For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), 3. 1% yield). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CVS: +3. 5%, HIMS: +161. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between SRXH and ALHC and HIMS and CVS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SRXH is a small-cap high-growth stock; ALHC is a small-cap high-growth stock; HIMS is a small-cap high-growth stock; CVS is a mid-cap income-oriented stock. CVS pays a dividend while SRXH, ALHC, HIMS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

SRXH

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
Run This Screen
Stocks Like

ALHC

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 16%
Run This Screen
Stocks Like

HIMS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

CVS

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 1.2%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SRXH and ALHC and HIMS and CVS on the metrics below

Revenue Growth>
%
(SRXH: 28.4% · ALHC: 33.3%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.